Ensysce Biosciences, Inc. announced that the PF614-201 study, 'A Randomized, Double-Blind, Placebo-Controlled Crossover Study of PF614 on Analgesic Response in the Cold Pressor Test in Healthy male Subjects' has completed enrollment. The goal of this exploratory Phase 2 PF614-201 study is to confirm the approximate time of onset for PF614 analgesic effects prior to initiation of Phase 3 efficacy evaluations.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5001 USD | -8.32% |
|
-3.83% | -52.82% |
05-28 | Ensysce Biosciences Back in Compliance With Nasdaq | MT |
05-20 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-52.82% | 3.79M | |
+34.14% | 51.12B | |
-6.54% | 39.4B | |
+34.92% | 38.48B | |
+12.62% | 26.36B | |
-12.11% | 26.22B | |
-13.43% | 20.96B | |
+43.73% | 14.02B | |
+31.81% | 12.49B | |
-4.54% | 11.61B |
- Stock Market
- Equities
- ENSC Stock
- News Ensysce Biosciences, Inc.
- Ensysce Biosciences, Inc. Announces Enrollment Completion for PF614-201 Clinical Study